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Hydrogen sulphide (H2S) has been identified as the third member of 
gasotransmitters, alone with nitric oxide (NO) and carbon monoxide (CO). It can be 
endogenously generated from cysteine by two enzymes, cystathionine β-synthase (CBS) 
and cystathionine γ-lyase (CSE). In the current study, the role of hydrogen sulfide (H2S) 
in the cardioprotection during ischemia/reperfusion was investigated. 
Given that Intracellular pH (pHi) is an important endogenous modulator of cardiac 
function and inhibition of Na+/H+ exchanger-1 (NHE-1) protects the heart by 
preventing Ca2+ overload during ischemia/reperfusion, the present study investigated 
the pH regulatory effect of H2S in rat cardiac myocytes and evaluate its contribution to 
cardioprotection. It was found that sodium hydrosulfide (NaHS), at a concentration 
range of 10 to 1000 μM, produced sustained decreases in pHi in the rat myocytes in a 
concentration-dependent manner. NaHS also abolished the intracellular alkalinization 
caused by trans-(±) 
-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide 
methane-sulfonate hydrate (U50,488H), which activates NHEs. Moreover, when 
measured with an NH4Cl prepulse method, NaHS was found to significantly suppress 
NHE-1 activity. Both NaHS and cariporide or [5-(2-methyl-5-fluorophenyl)furan-2- 
ylcarbonyl]guanidine (KR-32568), two NHE inhibitors, protected the myocytes against 
ischemia/reperfusion injury. The further functional study showed that perfusion with 
NaHS significantly improved pos-tischemic contractile function in isolated rat hearts 
vii 
 
subjected to ischemia/reperfusion. Blockade of phosphoinositide 3-kinase (PI3K) with 
2-(4-morpholinyl)-8-phenyl- 4H-1-benzopyran-4-one (LY294002), Akt with Akt VIII, 
or protein kinase G (PKG) with (9S,10R,12R)-2,3,9,10,11,12-hexahydro-10- 
methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg: 
3’,2’,1’-kl]pyrrolo[3,4-i][1,6]]enzodiazocine-10-carboxylic acid, methyl ester 
(KT5823) significantly attenuated NaHS-suppressed NHE-1 activity and/or 
NaHS-induced cardioprotection. Although KT5823 failed to affect NaHS-induced Akt 
phosphorylation, Akt inhibitor did attenuate NaHS-stimulated PKG activity.  
In conclusion, the current work demonstrated that H2S produced cardioprotection 
via the regulation of intracellular pH which is achieved by inhibition of NHE-1 activity. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Gasotransmitters 
1.1.1 Definition of gasotransmitters 
The term “gasotransmitter” was firstly introduced in 2002 (Wang 2002). 
Gasotransmitters, which includes nitric oxide (NO), hydrogen sulphide (H2S), carbon 
monoxide (CO), and possibly nitrous oxide (N2O), is a family of endogenous molecules 
of gases or gaseous signaling molecules. The following criteria should be met before a 
gas molecule can be categorized as a gasotransmitter. (i) It is a small molecule of gas; 
(ii) It is freely permeable to membranes; (iii) It is endogenously and enzymatically 
generated and its production is regulated; (iv) Its functions have been well and 
specifically defined at physiologically relevant concentrations; (v) exogenously 
applying of its counterpart can produce functions of this endogenous molecule; (vi) It 
should have specific cellular and molecular targets.  
 
1.2 Hydrogen sulfide is the third member of gasotransmitter family 
1.2.1 Physical and chemical properties of H2S 
Hydrogen sulphide (H2S) is a colorless, flammable and naturally occurring gas 
with a strong rotten egg smell. It is a small molecule soluble in water (1 g in 242 ml at 
20°C), organic solvents and lipophilic solvents (Lim, Liu et al. 2008; Li, Hsu et al. 
2009). As a weak acid with a pKa of 7.04, H2S can dissociate in water or plasma as 
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follows: H2S ↔ HS– + H+ (Wang 2002). H2S is lipophilic and thus readily permeable 
and diffusive in the plasma membranes.  
 
1.2.2 Past and current views of H2S 
    H2S was used to be viewed as a toxic gas which is more toxic than hydrogen 
cyanide (HCN) and CO, and an exposure of H2S at 300 ppm in air for 30 minutes will 
result in fatality (Pryor, Houk et al. 2006). Inhibition on cytochrome c oxidase and 
induction of cell death via formation of reactive oxygen species and mitochondrial 
depolarization can be the reasons for the toxicity of H2S. (Dorman, Moulin et al. 2002; 
Eghbal, Pennefather et al. 2004) Recently, H2S has been viewed as the third member 
of gasotransmitters, for the reasons that its concentration in the blood plasma of mice, 
rats and human is considerably high and its synthesizing enzymes, 
cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE), are identified. 
 
1.2.3 Biosynthesis of H2S 
H2S is produced endogenously from cysteine and homocysteine in reactions 
catalyzed by cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE).  These 
two enzymes are the main players in the metabolism of L-cysteine (Hughes, Bundy et al. 
2009) which is the main substrate of the generation of H2S. The expression of these two 
enzymes is highly tissue-specific; while CSE is largely expressed in the cardiovascular 
system, CBS predominates in the central nervous system (Chen, Poddar et al. 1999; 
Geng, Yang et al. 2004).  
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Figure 1 Three pathways of endogenous synthesis of H2S.  




1.2.4 Metabolism of endogenous H2S 
    Oxidation in mitochondria, methylation in cytosol and scavenging by 
methemoglobin or metallo- or disulfide-containing molecules are three major pathways 
in H2S metabolism (Wang 2002). Briefly, H2S is metabolized in mitochondria initially 
to thiosulphate which is further converted to sulfate which is the end-product and is 
eventually excreted by the kidney (Beauchamp, Bus et al. 1984; Lowicka and 
Beltowski 2007). Also, H2S could be methylated in the cytosol by thiol 
S-methyltransferase (TSMT) and be turned into methanethiol and 
dimethylsulfide(Furne, Springfield et al. 2001). Finally, H2S could be scavenged by 





Figure 2 Endogenous H2S synthesis and metabolism.  
CSE: Cystathionine gamma lyase; CBS: Cystathionine beta synthase; MST: 
Mercaptopyruvate sulfu rtransferase; CAT: Cysteine aminotransferase; TR: Thiosulfate 
reductase; TS: Thiosulfate sulfurtransferase; SO: Sulfite Oxidase; GSH: Glutathione; 
GSSG: Glutathione disulfide; RSH: Thiol Cys: Cysteine MetHb: Methhemoglobin 




1.3 Physiological functions of H2S in the cardiovascular system 
1.3.1 Vasorelaxant effects of H2S 
H2S showed its vasorelaxant effect through activating KATP channel in thoracic 
aorta (Zhao, Zhang et al. 2001). This effect was also observed in mesenteric arteries 
(Cheng, Ndisang et al. 2004), portal vein (Hosoki, Matsuki et al. 1997) and ileum 
(Teague, Asiedu et al. 2002). Moreover, H2S could decrease bold pressure when a bolus 
was injected into rats (Zhao, Zhang et al. 2001; Ali, Fazl et al. 2006). 
 
1.3.2 Physiological functions of H2S in the cardiovascular system 
H2S plays an important role in the regulation of heart function. Both endogenous 
and exogenous H2S protects heart from isoproterenol-induced myocardial injury by 
directly scavenging oxygen free radicals (Geng, Chang et al. 2004) and inhibiting the 
adenylyl cyclase/cAMP pathway or L-type calcium channel (Yong, Pan et al. 2008). 
Till now, plenty of studies have demonstrated that H2S could protect the heart from 
myocardial injury (Johansen, Ytrehus et al. 2006; Sivarajah, McDonald et al. 2006; Zhu, 
Wang et al. 2007). Moreover, H2S preconditioning (SP) mimicked cardiac protective 
effects produced by ischemic preconditioning (Pan, Feng et al. 2006). Although it is 
generally accepted that H2S could produce cardioprotective effects in the hearts 





1.4 Signaling Mechanisms of H2S 
1.4.1 Activation of KATP channels 
An ATP-sensitive potassium channel (KATP channel) is a type of potassium 
channel that is gated by ATP and composed of two kinds of subunits: the pore 
forming subunits, inwardly rectifying potassium channel subunits (KIR6.1 or KIR6.2), 
and the larger regulatory subunits, sulphonylurea receptor (SUR). They can be further 
identified by their position within the cell as the sarcolemmal KATP channel, 
mitochondrial KATP channel, and nuclear KATP channel (Zhuo, Huang et al. 2005). 
KATP channel is involved in metabolite regulation. In cardiomyocytes, energy is 
derived mostly from long-chain fatty acids and their acyl-CoA equivalents. During 
ischemia reperfusion, the oxidation of fatty acids slows down, which results in the 
accumulation of acyl-CoA and KATP channel opening (Koster, Knopp et al. 2001).  
    More importantly, many studies have demonstrated that the effect of H2S in 
cardiovascular system is related to the opening of KATP channels, such as the 
vasodilatory effect of H2S (Zhao, Zhang et al. 2001), the protective effect of H2S in 
cardiac myocytes (Bian, Yong et al. 2006; Sivarajah, McDonald et al. 2006), and the 
negative effect of H2S on myocardial contractility (Geng, Yang et al. 2004) 
 
1.4.2 Stimulation of MAP Kinases 
    Mitogen-activated protein (MAP) kinases are serine/threonine-specific protein 
kinases. MAPKs are involved in directing cellular responses to various stimuli and 
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regulate proliferation, cell survival, and apoptosis (Pearson, Robinson et al. 2001). The 
first-discovered MAPK was ERK1 (MAPK3). ERK1 and the closely related ERK2 
(MAPK1) are both involved in growth factor signaling. As regulators of cell 
proliferation, they have a highly specialized function. Also, c-Jun N-terminal kinases 
(JNKs), and p38 MAPKs have been well characterized in mammals. Both JNK and p38 
signaling pathways are responsive to stress stimuli, such as ultraviolet irradiation and 
heat shock, and are involved in cell apoptosis. 
Interestingly, studies have shown that ERK1/2 is one of the downstream target for 
H2S in HEK293 cells (Yang, Cao et al. 2004), human aorta smooth muscle cells (Yang, 
Sun et al. 2004; Yang, Wu et al. 2006), human monocytes (Zhi, Ang et al. 2007), and in 
cardiomyocytes (Hu, Chen et al. 2008). Although one of our studies has suggested the 
involvement of p38 MAP kinase in anti-inflammatory role of H2S (Hu, Wong et al. 
2007), this conclusion is not widely accepted.  
 
1.4.3 Other signaling mechanisms of H2S 
Moreover, researchers have recently found that pre- and post-conditioning with 
H2S produced cardioprotective effects against ischemic injury via regulation of protein 
kinase C (PKC), cyclooxygenase-2 (COX-2), NO, phosphoinositol-3-kinase 
(PI3K)/Akt and GSK3β pathways (Bian, Yong et al. 2006; Hu, Pan et al. 2008; Yong, 
Lee et al. 2008; Yao, Huang et al. 2010). More importantly, endogenous H2S was found 
to contribute to the cardioprotection induced by ischemic pre- and post-conditioning 
(Bian, Yong et al. 2006; Pan, Feng et al. 2006; Yong, Lee et al. 2008). In addition, H2S 
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may also produce a pro-angiogenic effect (Cai, Wang et al. 2007), which can contribute 
to its cardioprotective action. These results suggest that H2S not only ameliorates the 
pathological process of ischemic heart disease but may also act as a cardioprotective 
regulator. 
 
1.5 H2S under pathological condition 
    During pathological process, a change of H2S level has been reported in different 
animal models. In the cardiovascular system, this change is usually relevant to CSE 
activity. Scientists found that H2S concentration decreased significantly in patients with 
coronary heart disease (Jiang, Wu et al. 2005), in myocardial tissue subjected to 
myocardio injury (Geng, Chang et al. 2004) and in medium of isolated cardiomyocytes 
treated with ischemia solution (Bian, Yong et al. 2006). On the other side, elevation of 
H2S level was also observed by different groups in a LPS-injection septic shock mice 
model (Li, Bhatia et al. 2005), in endotoxemia rat model (Collin, Anuar et al. 2005) and 
in the liver and pancreas in Streptozotocin-induced diabetic rats (Yusuf, Kwong Huat et 
al. 2005). 
 
1.6 intracellular pH and ion exchangers 
    Intracellular pH (pHi) is an important modulator of cardiac function, influencing 
processes as varied as contraction, excitation and electrical rhythm. Regulation of pHi 
is required for the maintenance of an environment appropriate for cellular activities. 
Hence, pHi has to be tightly controlled within a narrow range, largely through the 
10 
 
activity of transporters such as Na+/H+ exchanger (NHE-1) and Cl-/HCO3- exchanger 
(CBE). Protons are produced metabolically within the heart.  These ions are highly 
reactive with cellular proteins and they must be removed if cardiac function is to be 
maintained. During ischemia, lactic acid accumulation causes significant intracellular 
acidosis, which stimulates NHE-1. This minimizes the intracellular acidosis and causes 
an increase in intracellular sodium ([Na+]i). The protons leaving the cell accumulate 
produce an extracellular acidosis. During reperfusion, the extracellular protons are 
flushed away and the activity of NHE-1 would then lead to a rapid recovery of pHi and 
a rise in [Na+]i. The latter could eventually result in Ca2+ entry by means of Na+/Ca2+ 
exchangers. Therefore, it is well accepted that inhibition of NHE-1 protects against 
some of the damaging effects of ischemia. We recently reported that H2S regulates pHi 










Endoplasmic reticulum 7.2 
Golgi network 6-6.7




Table 1 The pH values of individual cellular organelles and compartments in a 
prototypical mammalian cell  





Figure 3 Ion exchangers regulate intracellular pH 
 





1.7 Hypotheses and Objectives 
    Contributions from scientists studying H2S effects on cardioprotection help us to 
unveil the physiological roles of H2S. Until now, most of the studies of downstream 
target of H2S have focused on protein kinase C (PKC), KATP channels, 
cyclooxygenase-2 (COX-2), p42/44-mitogen activated protein kinase (MAPK) and 
phosphoinositol-3-kinase (PI3K)/Akt pathways. However, whether or not H2S can also 
produce cardioprotective effect via regulation of pHi in hearts by affecting NHE-1 
activity is still unknown. Thus, my project was therefore designed to determine whether 
the mechanisms of cardioprotection produced by H2S against ischemia/reperfusion 
involve the effect of H2S on pHi in isolated cardiac myocytes and rat hearts, and to 
investigate whether this mechanism involves the activation of PI3K/Akt pathway 





CHAPTER 2 MATERIALS and METHODS 
 
2.1 Isolation of rat ventricular cardiac myocytes 
The study protocol was approved by the Institutional Animal Care and Use 
Committees (IACUC) of National University of Singapore. Sprague-Dawely rats 
(190~210 g, male) were anesthetized with intraperitoneal (i.p.) injection of a 
combination of ketamine (75mg/kg) and xylazine (10mg/kg). Heparin (1000 IU) was 
administered i.p. to prevent coagulation during removal of the heart. The rat hearts was 
quickly excised, mounted on a Langendorff apparatus, and perfused in a retrograde 
fashion via the aorta with calcium-free Tyrode's solution (in mmol/L: 137 NaCl, 5.4 
KCl, 1 MgCl2, 10 HEPES, 10 Glucose, pH 7.4) at 37 °C. After 5 min the perfusion 
solution was changed to the Tyrode's solution containing 1 mg/ml collagenase type I 
and 0.28 mg/ml protease (type XIV) and perfused for a further 25-30 min. The 
perfusion solution was then changed to Ca2+-Tyrodes solution containing 2 × 10−4mol/L 
CaCl2 without enzymes for an additional 5 min. The ventricular tissue was then cut into 
small pieces in a Petri dish containing pre-warmed Ca2+ Tyrode's solution and shaken 
gently to ensure adequate dispersion of dissociated cardiac myocytes. A 2.5 × 10−4 
meter mesh screen was used to separate the isolated cardiac myocytes from cardiac 
tissue. The cells were then washed three times in Ca2+-Tyrode's solution and collected 
by centrifugation (700 rpm, for 1 min). Ca2+ concentration of the Tyrode's solution was 
increased gradually to 1.25 × 10−3 mol/L in 20 min. More than 80% of the cells were 
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rod-shaped and impermeable to trypan-blue. The cells were allowed to stabilize for 30 
min before any experiments.  
 
2.2 pHi measurements in rat ventricular cardiac myocytes 
The isolated cardiac myocytes were incubated with 1 μM 
2,7-biscarboxyethyl-5,6-carboxyfluorescein/acetoxymethyl ester (BCECF/ AM) for 30 
min in the dark at room temperature. The unincorporated dye was then removed by 
washing the cardiac myocytes twice in fresh incubation solution. The 
membrane-permeable ester was trapped inside the myocytes because of hydrolyzation 
by esterases and fluoresced pH-dependently. The loaded rat cardiac myocytes were 
kept in the dark at room temperature for another 30 min before pHi measurement to 
allow the BCECF/AM in the cytosol to de-esterify.  
The BCECF/AM-loaded rat cardiac myocytes were transferred to the stage of an 
inverted microscope (Nikon, Tokyo, Japan) in a perfusion chamber at room 
temperature. The inverted microscope was coupled with a dual-wavelength excitation 
spectrofluorometer (Intracellular Imaging Inc., Cincinnati, OH). Cells were perfused 
with Krebs’ solution (117 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 
1.25 mM CaCl2, 25 mM NaHCO3, and 11 mM glucose, pH 7.4). Drugs were then added 
directly into the bath solution during pHi measurements, and the change in fluorescent 
intensity was monitored. The pH-dependent fluorescent signal of BCECF/AM was 
obtained by illuminating at excitation wavelengths of 490 nm (F490) and 440 nm 
(F440). The ratio of signals obtained at F490 and F440 was used to represent pHi. The 
16 
 
calibration of BCECF/AM signals was performed by setting pHi to extracellular pH 
with 10 μM nigericin in Krebs’ solution. The extracellular pH was changed by 
perfusion with Krebs’ solution at pH 6.8, 7.4, 8, or 10. From these corresponding pH 
and fluorescence measurements, a graph was constructed and used for the translation of 
fluorescence values into pHi values. 
 
2.3 Determination of NHE-1 activity 
NHE-1 activity in cardiac myocytes was assessed by measuring the recovery rate 
of cells from intracellular acidification. Cells were perfused with HEPES-buffered 
solution containing 137 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.5 mM MgCl2, 10 
mM HEPES, and 10 mM glucose, adjusted to pH 7.4 with NaOH. Myocytes were 
maintained at 25°C throughout and subjected to intracellular acidosis by transient 
exposure to 20 mM NH4Cl (6 min at 25°C) with subsequent washout for 8 min. 
Because NH4+ enters the cell at a slow, but significant, rate on transporter pathways, 
this feature is used to acid-load the cytoplasm (Fro¨hlich and Wallert, 1995). Washout 
of NH4Cl therefore imposes an acid load by trapping protons into the myocytes. 
Subsequently, myocytes recovered from this acid load via the activity of NHE-1. The 
slope of pHi recovery determines the sarcolemmal NHE-1 activity (Fro¨hlich and 
Wallert, 1995). To assess NHE-1 activity of myocytes in the presence of H2S, 0.1 mM 
sodium hydrosulfide (NaHS) was added to the cells 10 min before intracellular 




2.4 Determination of CBE activity 
CBE activity was assessed by measuring the recovery rate of cells from 
intracellular alkalinization. Intracellular alkalinization was introduced by a rapid 
addition of 20 mM NH4Cl to bathing solution. Exposure of cells to NH4Cl results in 
diffusion of NH3 across cell membranes, leading to rapid intracellular alkalinization 
(Furtado 1987). pHi gradually decreases from the peak of alkalinization due to efflux of 
HCO3- via activity of CBE, that is, a recovery from alkali load (Xu and Spitzer 1994). 
The slope of the pHi decrease determines the rate of recovery from the peak of 
alkalinization and is measured in ΔpH/msec. To assess the CBE activity of cells in the 
presence of H2S, 0.1 mM NaHS was added 10 min prior to intracellular alkalinization 
and myocytes were perfused with NaHS-containing HEPES-buffered solution.  
 
2.5 Ischemia/reperfusion in isolated rat ventricular myocytes 
For the cardiac myocytes ischemia/reperfusion experiments, simulated ischemia 
solution (i.e. glucose-free Krebs buffer containing 10 mM 2-deoxy-D-glucose 
(2-DOG), an inhibitor of glycolysis and 10 mM sodium dithionite (Na2S2O4), an 
oxygen scavenger, pH 6.6) was applied. The use of simulated ischemia solution in this 
way produces a mixture of effects including metabolic inhibition, anoxia and acidosis. 
This method was adapted from previous publications  (Ho, Wu et al. 2002). In brief, 
after dissociation, the cardiac ventricular myocytes were allowed to stabilize for 30 
min before the experiment commenced. Ventricular myocytes were subjected to 
ischemia solution for 30 min followed by reperfusion with Dulbecco's Modified 
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Eagle's Medium (DMEM) solution for up to one hour. NaHS or cariporide was 
applied 10 min before and during ischemia, respectively. Myocyte viability was 
determined at the end of reperfusion for a certain period as specified in the individual 
results. 
 
2.6 Cell viability assay for rat ventricular cardiac myocytes 
    Trypan blue exclusion was used as an index of myocyte viability.  At the end of 
reperfusion, cardiac myocytes were incubated with 0.4% (w/v) trypan blue dye 
(Sigma) for 3 min. Those unstained were termed to be non-blue cells. The ratio of 
non-blue cells/total cells was determined in a hemocytometer chamber under a light 
microscope.  
 
2.7 PKG activity assay 
Cyclic GMP-dependent protein kinase assay (Cyclex, MBL International 
Corporation) was used to measure PKG activity. The isolated myocytes were divided 
into different treatment groups: vehicle + ischemia group (myocytes treated with 
vehicle and subjected to simulated ischemia solution for 30 min), NaHS + ischemia 
group (myocytes were pretreated with NaHS at 0.1 mM for 10 min before subjected to 
ischemia), Akt VIII + NaHS + ischemia (myocytes were treated with Akt VIII  at 1 µM 
for 10 min and then NaHS at 0.1 mM for 10 min followed by ischemia for 30 min), and 
KR + NaHS + ischemia (myocytes were treated with KR-32568 at 1 μM for 10 min  
and then NaHS at 0.1 mM for 10 min followed by ischemia for 30 min).  
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Protein extraction was performed, and 100μl of each sample was transferred into a 
96-well plate pre-coated with a substrate corresponding to recombinant G-kinase 
substrate and incubated at 30℃ for 30 min. During the incubation, the substrate was 
phosphorylated by PKG in the protein sample, which was measured by incubating the 
substrate with a horseradish peroxidase conjugate of 10H11, a anti-phospho-G-kinase 
substrate threonine 68/119 specific antibody, for 1 hour at room temperature. Then the 
chromogenic substrate tetra-methylbenzidine (TMB) was added into the wells by 
adding the substrate reagent, which converted the colorless solution to a blue solution. 
After the stop solution was added into the wells, Absorbance was determined at 450 nm 
using a 96 well microplate reader (Tecan Systems Inc., U.S.A.). Experiments of “Test 
Sample cGMP minus” group and “ATP minus” group were conducted as quality 
controls of our assay.  
 
2.8 Western blotting analysis 
    To examine the effect of NaHS on non-ischemic myocytes, the isolated cardiac 
myocytes were subjected to NaHS or vehicle treatment for 30 min. To test the action of 
NaHS on cardiac myocytes subjected to ischemic insults, NaHS (0.1 mM) was added to 
the myocytes for 10 min before and during ischemia for 30 min. To examine the 
regulatory effect of PKG on Akt phosphorylation, KT5823 (0.5 µM), a specific 
inhibitor of PKG, was added 10 min before NaHS treatment. At the end of treatment or 
ischemia, myocytes were gently washed twice with ice-cold PBS, homogenized in 
chilled lysis buffer containing 125 mM NaCl, 25 mM Tris (pH 7.5), 5 mM EDTA, 1% 
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NP-40, 1 mM NaF, 2 mM Na3VO4 and protease inhibitor (Roche) and then shaken on 
ice for one hour. After that, the lysates were centrifuged at 13,000 ×g for 10 min at 4°C.  
The supernatants were then collected and denatured by SDS sample buffer, and the 
epitopes were exposed by boiling the protein samples for 5 min in a dry heat block. 
Equal amount of proteins were loaded and separated on 12% SDS-PAGE gel, and then 
transferred onto nitrocellulose membrane. The membrane was then probed with 
antibodies against phosphorylated- and total Akt (Cell Signaling, 1:1000) and second 
antibody(Santa Cruz Biotechnology, CA, USA). Immunoreactivity was detected using 
an ECL Western blot detection kit (Amersham Biosciences, USA). 
 
2.9 Langendorff heart preparation and haemodynamic assessment 
Hearts were quickly excised, mounted on a Langendorff apparatus, and perfused in 
a retrograde fashion via the aorta with Kreb’s buffer (137 mM NaCl, 2.5 mM CaCl2, 5 
mM KCl, 1.2 mM MgSO4, 10 mM HEPES, and 10 mM glucose, pH 7.4) at 37oC. The 
hearts were perfused at a constant pressure of 80 mmHg. These were subsequently 
submitted to 30 min stabilization, 30 min global no-flow ischemia and 1 h reperfusion. 
NaHS in Kreb’s solution was perfused into heart for 10 min before the global no-flow 
ischemia was commenced. During no-flow ischemic period, no solution was perfused. 
Hearts was continued to be exposed to the solution containing NaHS during the no-flow 
ischemia period. 
Left ventricular pressure was monitored using a latex balloon connected to a 
pressure transducer (Powerlab, Australia). The balloon volume was adjusted to obtain a 
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left ventricular end-diastolic pressure (LVeDP) of 5–8 mmHg. All data were digitally 
converted and stored on a computer for analysis (Powerlab, Australia). 
 
2.10 Chemicals and reagent 
    Nigericin, U50,488H, NH4Cl, Sodium hydrosulfide (NaHS), KR-32568, 
collagenase I, protease XIV and Trypan blue dye (0.4%) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). 
2,7-biscarboxyethyl-5,6-carboxyfluorescein/AM (BCECF/AM) were obtained from 
Molecular Probes (Eugene, OR, USA). KT5823, Akt VIII and LY294002 were 
obtained from Merck (Nottingham, UK). Nigericin is dissolved in ethanol. All other 
chemicals were dissolved in water except KR-32568, KT5823, LY294002, 
BCECF/AM and DIDS, which were dissolved in dimethylsulphoxide (DMSO).  
Cariporide ([4-Isopropyl-3-(methylsulfonyl)benzoyl]guanidine methanesulfonate, 
HOE-642) was a gift from Sanofi Aventis, Germany. In our preliminary study, we 
tested the dose-dependent effect of cariporide at doses of 1, 5, 7 µM on cell viability 
and NHE activity in the isolated rat cardiac myocytes and found that cariporide 
produced significant effects only when at a concentration of 7 µM. Therefore, this 
concentration was used in all further experiments.  
NaHS was used as H2S donors. The use of NaHS enables us to define the 
concentrations of H2S in solution more accurately than bubbling H2S gas. NaHS at 
concentrations used in our work did not change the pH of the medium (Geng, Yang et 




2.11 Statistical analysis 
Values presented are Mean  SEM. Paired Student’s t-test was used to determine 
the difference in fluorescent signal before and after treatment in the same cell. One-way 
analysis of variance (ANOVA) was used with a post-hoc (Bonferroni) test to determine 





CHAPTER 3 RESULTS 
 
3.1 Cardioprotection induced by hydrogen sulfide in rat hearts and 
rat cardiac myocytes 
3.1.1 NaHS produced protective effect on hemodynamic function in isolated 
hearts 
Hemodynamic disorders always lead to the disturbances in the blood movement 
and the interference in transfer of O2 and glucose into the cells. To examined the effect 
of NaHS on contractile function of isolated heart during ischemic reperfusion, I 
perfumed hemodynamic assessment. Figure 5 shows the representative tracings of the 
effect of NaHS (100 μM) on isolated hearts subjected to ischemia/reperfusion. Hearts 
of control group could not function normally, however NaHS-treated hearts restored 
beating after several minutes of reperfusion. 
 
Figure 5 Representative tracings of left ventricular developed pressure (LVDP) of 





During the whole period of ischemia/reperfusion, all parameters of hemodynamics 
were recorded and some of them were chosen for analysis. 
Left ventricular developed pressure (LVDP) was calculated as the difference 
between left ventricular systolic pressure and left ventricular diastolic pressure. As 
shown in Figure 6, LVDP of NaHS group increased to 47.81% ± 5.59% of preischemia 
value at the end of 15 min reperfusion, while LVDP of control group didn’t recovered 
at all and was kept at 7.67% ± 3.19% of preischemia value, which indicates that 
NaHS treatment effectively restored LVDP during the reperfusion period. 
 
Figure 6 The cardioprotective effect of H2S on left ventricular developed 
pressure (LVDP).  
Pretreatment with NaHS (100μM) for 10 min significantly attenuated the effects of 
ischemia/reperfusion on LVDP. Mean±S.E.M. (n = 6–8). *, p<0.05; **, p<0.01; ***, 
p<0.001 versus the corresponding values in the control group.  
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Figure 7 demonstrates the significant difference of left ventricular end diastolic 
pressure (LVeDP), the minimum pressure recorded during diastoles, between control 
group and NaHS group. LVeDP of NaHS group slowly decreased to 762.92% 
±148.21% of the value before ischemia, while LVeDP of control group at 15 min of 
reperfusion remained at 1273.32% ± 232.00% of the value before ischemia. Our data 
suggest that hearts of control goup could not totally relax during reperfusion. 
 
Figure 7 The cardioprotective effect of H2S on left ventricular end diastolic 
pressure (LVeDP).  
Pretreatment with NaHS (100μM) for 10 min significantly attenuated the effects of 
ischemia/reperfusion on LVeDP. Mean±S.E.M. (n = 6–8). *, p<0.05; **, p<0.01; ***, 
p<0.001 versus the corresponding values in the control group. 
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Contractility (+dP/dt) was represented by the maximum gradient during systoles 
and compliance (-dP/dt) was represented by the minimum gradient during diastoles. 
Figure 8&9 show that pretreatment with NaHS restored contractility and compliance of 
rat hearts to 46.20% ±7.23% and 79.79% ±12.07% respectively, when compared with 
the preischemia value. On the other hand, the recovery of +dP/dt and -dP/dt of control 
group was limited to only 5.35% ± 2.31% and 7.02% ± 3.03% of preischemia value at 
the first 15 min of reperfusion. These data indicate that NaHS treatment significantly 
restored the contractility and compliance of hearts subjected to ischemia/reperfusion 
injury. 
 
Figure 8 The cardioprotective effect of H2S on maximum gradient during 
systoles (+dP/dt).  
Pretreatment with NaHS (100μM) for 10 min significantly attenuated the effects of 
ischemia/reperfusion on +dP/dt. Mean±S.E.M. (n = 6–8). *, p<0.05; **, p<0.01; ***, 






Figure 9 The cardioprotective effect of H2S on minimum gradient during 
diastoles (-dP/dt).  
Pretreatment with NaHS (100μM) for 10 min significantly attenuated the effects of 
ischemia/reperfusion on -dP/dt. Mean±S.E.M. (n = 6–8). *, p<0.05; **, p<0.01; ***, 




Taken together, these data suggest that H2S elicited significant cardioprotective 
effect on hemodynamic function represented by LVDP, LVeDP, +dP/dt, and -dP/dt at 




3.1.2 Effects of NaHS on cell viability in rat cardiac myocytes subjected to 
ischemia/reperfusion insults 
    Since NHE-1 inhibition may protect hearts against ischemia/reperfusion-induced 
injury (Karmazyn 2001), we further tested whether NaHS could also protect the cardiac 
myocytes against ischemia/reperfusion injury. The experimental protocol is shown in 
Figure 10A and described in the section on Materials & Methods. As shown in Figure 
10B, both NaHS and cariporide significantly increased cell viability in ventricular 
myocytes subjected to ischemia (30 min)/reperfusion (10 min), suggesting that like the 
NHE-1 inhibitor, NaHS may also protect cardiac myocytes against 
ischemia/reperfusion-induced injury. We further examined the time-course for the 
cardioprotection offered by NaHS. As shown in Figure 10C, NaHS (100 µM) treatment 
protected cardiac myocytes subjected to ischemia (30 min)/reperfusion for up to 30 and 
60 min. These data suggest that the cardioprotective effects of NaHS may last at least 
for 1 h after reperfusion.  
    To examine whether the effect of NaHS was additive to that caused by NHE-1 
inhibition, we compared the cardioprotective effects conferred by NaHS, KR-32568 
(1µM, a potent NHE-1 inhibitor) alone or in combination (NaHS+KR-32568). As 
shown in Figure 10D, NaHS produced comparable protective effects to those caused by 
KR-32568 alone and the combination treatment. These data suggest that H2S and the 




Figure 10 Effect of NaHS on cell viability in cardiac myocytes subjected to 
ischemia/reperfusion (I/R).  
A, experimental protocol. The cardiac myocytes were treated with vehicle, NaHS (100 
μM), or cariporide (7 μM) for 10 min before and during the simulated ischemia. After 
ischemia for 30 min, the simulated ischemia buffer was washed out with fresh 
Dulbecco’s modified Eagle’s medium solution, and cell viability was measured at the 
end of reperfusion with a Trypan blue exclusion assay. B, both NaHS and cariporide 
significantly increased the cell viability of cardiac myocytes subjected to ischemia (30 
min)/reperfusion (10 min). C, group data show the protective effects of NaHS against 
the cardiac myocytes injury induced by ischemia and reperfusion for 10, 30, and 60 min. 
D, treatment with NaHS (100 μM) and KR (KR-32568; 1 μM) alone or a combination 
of both protected myocytes against ischemia/reperfusion insult to a similar extent. 
Mean±S.E.M. (n=4–6). #, P<0.05 versus the vehicle-treated group. *, p<0.05; ***, 
p<0.001 versus the corresponding value in the control group. †, P<0.05; ††, P<0.01 





3.2 NaHS induced cardioprotection via regulation of intracellular pH 
3.2.1 Effect of NaHS on pHi in the rat ventricular myocytes 
As shown in Figure 11A, application of NaHS (an H2S donor, 100 μM), but not 
Krebs’ solution, induced an obvious decrease in pHi in the isolated ventricular 
myocytes. The effect of H2S occurred rapidly after NaHS administration, suggesting 
that H2S readily diffused through the cell membrane and influenced pHi. The decrease 
in pHi by NaHS mimicked the effect of cariporide (7 μM), a selective NHE-1 inhibitor. 
The concentration-dependent response is shown in Figure 11B. NaHS at a 
concentration range from 10 to 1000 μM (yielding approximately 3.3–330 μM H2S) 
produced concentration-dependent decreases in pHi in the rat cardiac myocytes. The 
strongest effect was obtained with NaHS at 100 μM. For this reason, 100 μM NaHS 




Figure 11 NaHS induces intracellular acidosis in the single cardiac myocyte.  
pHi was measured in cardiac myocytes loaded with BCECF/AM by a dual-wavelength 
excitation spectrofluorometer. A, representative tracings showing the effect of vehicle 
(Krebs), NaHS (100 μM), and cariporide (7 μM) on intracellular pHi. B, pooled data 
show the effect of NaHS (10, 100, and 1000 μM) and cariporide on pHi. Results are 





3.2.2 Effect of NaHS on NHE-1 activity in rat ventricular myocytes 
We had reported previously that U50,488H stimulates NHE-1 activity in cardiac 
myocytes (Bian, Wang et al. 1998). As shown in Figure 12A, U50,488H at 30 μM 
significantly increased the pHi in the isolated ventricular myocytes. Both cariporide (7 
μM) and NaHS (100 μM) abolished this effect, suggesting that, like cariporide, H2S 
may also inhibit NHE-1 activity. 
 
 
Figure 12 Both NaHS and cariporide abolish the pH regulatory effect of 
U50,488H.  
A, representative tracings demonstrating the effect of NaHS (100 μM) and cariporide (7 
μM) on U50,488H-induced intracellular alkalinization. NaHS and cariporide were 
added 6 min before exposure to U50,488H (30 μM) for another 10 min. B, group data 
are shown as mean±S.E.M. (n=21–29). *, p<0.001 versus the value of pHi change in the 




To verify the involvement of NHE-1 in the action of NaHS, we determined the 
activity of NHE-1 in cardiac myocytes by measuring the recovery rate of cells from 
intracellular acidification (Frohlich and Wallert 1995). Figure 13A shows the 
representative tracings of pHi in individual ventricular myocytes subjected to 
intracellular alkalinization. Transient application of NH4Cl loads the cell with alkali, 
thus inducing a significant elevation in pHi. Subsequent washout with NH4Cl imposes a 
strong acid load by trapping protons in the myocytes and thus induces intracellular 
acidification. As shown in Figure 13B&C, both NaHS and cariporide significantly 






Figure 13 Effect of NaHS on NHE-1 activity in the cardiac myocytes.  
A, representative tracing showing the intracellular pH changes with a typical NH4Cl 
prepulse method. Myocytes were subjected to intracellular acidosis by transient (6 min) 
exposure to 20 mM NH4Cl and subsequent washout and perfused with 
HEPES-buffered solution for 8 min. The slope of pHi recovery determines the 
sarcolemmal NHE-1 activity. B, representative tracings for pHi recovery from 
intracellular acidification caused by NH4Cl washout with and without NaHS or 
cariporide treatment. The triangles represent the fitted slopes of pHi recovery, 
indicative of NHE-1 activity. C, mean value showing that NaHS and cariporide 





3.2.3 Effect of NaHS on CBE activity in the isolated ventricular myocytes 
    Given that CBE is the main acid loader in cardiac myocytes, we also determined its 
activity by perfusing NH4Cl in the presence and absence of NaHS. NH4Cl perfusion is a 
widely adopted method to measure the capacity of CBE to maintain pHi (Xu and 
Spitzer 1994). NH4Cl loads the cells with alkali, resulting in a significant elevation in 
pHi. As an acid loader, CBE may consequently activate and extrude HCO3- in exchange 
for Cl- which eventually restores the pHi to normal. Therefore, the slope of the pHi 
recovery phase provides a measure of CBE activity. As shown in  Figure 14, H2S 
inhibits the activity of CBE. Since inhibition of CBE alone induces intracellular 
alkalization, instead of acidification, these data indicate that the intracellular 






Figure 14 Effect of NaHS on CBE activity in cardiac myocytes.  
A, representative tracings for pHi recovery from intracellular alkalinization caused by 
the rapid addition of NH4Cl into bath solution with and without NaHS treatment. The 
triangles represent the fitted slopes of pHi recovery, indicative of CBE activity. B, mean 
value showing that NaHS significantly inhibited CBE activity. Mean±S.E.M. 




3.3 The effect of NaHS on NHE-1 activity is mediated by PI3K/Akt 
and protein kinase G (PKG) pathways 
    Since activation of PI3K/Akt (Snabaitis, Cuello et al. 2008) or PKG (Perez, Piaggio 
et al. 2007) inhibits NHE-1 activity, we examined whether the effect of H2S involves 
these pathways. As shown in Figure 15A, blockade of PI3K with LY294002 (1 µM) or 
PKG with KT5823 (0.5 µM), neither of which had a significant effect on NHE-1 
activity, produced marked attenuation of the inhibitory effect of NaHS on NHE-1 
activity. These data suggest that the activation of PI3K/Akt and PKG may somehow be 
involved in the inhibitory effect of NaHS on NHE-1 activity.  
    We then investigated the effect of NaHS on PKG by measuring its activity with a 
semi-quantitative immunoassay kit. As shown in Figure 15B, NaHS significantly 
increased the PKG activity in the myocytes subjected to ischemia.  Pretreatment with 
Akt VIII, the Akt inhibitor, but not KR-32568 (KR, 1 μM), an NHE-1 inhibitor, 
abolished this effect. This implies that activation of Akt by H2S is upstream to that of 
PKG.  
Moreover, pretreatment with KT5823 for 10 min failed to attenuate 
NaHS-stimulated Akt phosphorylation (Figure 15C). The similar effect was also 
observed under ischemic conditions. Ischemia for 30 min significantly down-regulated 
Akt phosphorylation, which was reversed by NaHS (100 µM) pretreatment for 10 min. 
Blockade of PKG with KT5823 also failed to attenuate the effect of H2S on Akt 
phosphorylation during ischemia (Figure 15D). Taken together, our data clearly suggest 
that the activation of PKG is secondary to the NaHS-induced Akt activation but 
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Figure 15 Role of PI3K/Akt and PKG in NaHS-suppressed NHE-1 activity.  
A, blockade of PI3K/Akt with LY294002 (1 μM) or PKG with KT5823 (0.5 μM) 
significantly attenuated the effects of H2S on NHE-1 activity. Mean±S.E.M. (n=5–9). *, 
p<0.01 versus control. †, P<0.05; ††, p<0.01 versus the NaHS treated group. B, PKG 
activity in the isolated cardiac myocytes was determined with a semiquantitative 
immunoassay kit. Group data were obtained from five independent experiments. *, 
P<0.01 versus ischemia group. †††, P<0.001 versus NaHS plus ischemia group. C and 
D, effect of NaHS (100 μM) on Akt phosphorylation in cardiac myocytes in the 
presence or absence of KT5823 (0.5 μM; KT) in normal (C) and ischemic (D) cardiac 
myocytes. Pretreatment with KT5823 for 10 min failed to affect the stimulatory effect 
of NaHS on Akt phosphorylation in cardiac myocytes. The cardiac myocytes were 
pretreated with NaHS for 10 min and remained in contact with NaHS during ischemia 
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for 30 min. At the end of ischemia, the myocytes were harvested and subjected to 
Western blot analysis. The representative gels show the levels of phosphorylated Akt 
(p-Akt) and total Akt (t-Akt) in the myocytes subjected to various treatments. 
Mean<S.E.M. (n=8). #, p<0.05; ##, p<0.01 versus vehicle-treated myocytes without 





We further confirmed that the cardioprotection offered by NaHS is mediated by 
PI3K/Akt/PKG pathway. As shown in Figure 16, the heart contractile function 
presented by LVDP and ±dP/dt of the LY+NaHS group could not be restore as that of 
NaHS group did, indicating that the effect of NaHS on isolated hearts was also 
alleviated by LY294002 (1 µM, a PI3K inhibitor). However, LY294002 failed to 
completely block the action of NaHS, as the effect of NaHS on LVeDP was not 
alleviated at all. As shown in Figure 17&18, similar conclusion can be drawn when Akt 
VIII (1µM, a specific Akt inhibitor) and KT5823 (0.5 µM, a PKG inhibitor) were 
administrated to block Akt and PKG respectively, that Akt VIII and KT5823 could only 
obstruct the action of NaHS on LVDP and ±dP/dt but not on LVeDP. These data suggest 
that NaHS-induced cardioprotection is, at least partly, mediated by PI3K/Akt and PKG 
pathways. It is interesting to note that blockade of PI3K/Akt or PKG had no significant 
effect on NaHS-induced protection on LVeDP. These data imply that the protective 










Figure 16 LY294002 blocks the cardioprotective effect of H2S on heart 
contractile function by inhibiting PI3K activity. 
This figure shows the role of PI3K in the cardioprotection of H2S on heart contractile 
function in control, NaHS, LY+NaHS, and LY groups. Blockade of PI3K with 
LY294002 (1 μM), which alone had no effect, significantly attenuated the effects of 
H2S on heart contractile function. Inhibitors were given 10 min before the addition of 
NaHS for 10 min followed by no flow ischemia. Mean<S.E.M. (n = 5–8). *, p<0.05; **, 
p<0.01; ***, p<0.001 versus the corresponding values in the control group. +, p<0.05; 







Figure 17 Akt VIII blocks the cardioprotective effect of H2S on heart contractile 
function by inhibiting Akt activity. 
This figure shows the role of Akt in the cardioprotection of H2S on heart contractile 
function in control, NaHS, AKTVIII+NaHS, and AKTVIII groups. Blockade of Akt 
with Akt VIII (1 μM), which alone had no effect, significantly attenuated the effects of 
H2S on heart contractile function. Inhibitors were given 10 min before the addition of 
NaHS for 10 min followed by no flow ischemia. Mean<S.E.M. (n = 5–8). *, p<0.05; **, 
p<0.01; ***, p<0.001 versus the corresponding values in the control group. +, p<0.05; 







Figure 18 KT5823 blocks the cardioprotective effect of H2S on heart contractile 
function by inhibiting PKG activity. 
This figure shows the role of PI3K in the cardioprotection of H2S on heart contractile 
function in control, NaHS, KT+NaHS, and KT groups. Blockade of PKG with KT5823 
(0.5 μM), which alone had no effect, significantly attenuated the effects of H2S on heart 
contractile function. Inhibitors were given 10 min before the addition of NaHS for 10 
min followed by no flow ischemia. Mean<S.E.M. (n = 5–8). *, p<0.05; **, p<0.01; ***, 
p<0.001 versus the corresponding values in the control group. +, p<0.05; ++, p<0.01 





CHAPTER 4 DISCUSSION 
 
This study is aimed to investigate the possible mechanism and signaling pathways 
involved in the cardioprotection, induced by H2S, the third member of gasotransmitter 
family, against ischemia/reperfusion. 
Previous studies from our and other groups have found that H2S plays a critical 
role in protecting the heart against ischemic injury (Geng, Chang et al. 2004; Geng, 
Yang et al. 2004).  In the current study, our data showed that H2S elicited 
cardioprotection on hemodynamic function and cell viability during 30min no-flow 
ischemia and reperfusion. Mechanisms of these results were explored. 
    In the heart, intercellular pH influences contractility (Vaughan-Jones, Eisner et al. 
1987; Kohmoto, Spitzer et al. 1990) and affects the generation of arrhythmias (Orchard 
and Cingolani 1994; Ch'en, Vaughan-Jones et al. 1998). In the present study, we found 
that NaHS over a concentration range of 10-1000 M decreased pHi in a 
concentration-dependent manner.  
Furthermore, NaHS abolished the U50,488H-stimulated NHE activity. The assay 
of NHE activity further confirms that H2S-induced intracellular acidosis is mediated by 
inhibition of NHE-1 activity. NHE-1 is an important acid extruder in cells. It is well 
recognized that NHE-1 inhibition may produce cardioprotection. We also found in the 
present study that both NaHS and NHE-1 inhibitor protected hearts against ischemic 
injury. However, the combination of two drugs did not produce any additive or 
synergistic cardioprotective effect. Our study therefore suggests that NaHS produced 
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cardioprotection via the inhibition of NHE-1 activity.  
    The signaling mechanism for the action of H2S on NHE-1 was also investigated. It 
has been previously reported that activation of Akt phosphorylates NHE-1 and thus 
inhibits its activity (Snabaitis, Cuello et al. 2008). We therefore tested whether the 
inhibition of NHE-1 activity caused by H2S is mediated by PI3K/Akt pathway. We 
found that NaHS treatment stimulated Akt phosphorylation in both normal and 
ischemic cardiac myocytes. Our finding is in agreement with a recent report that H2S 
protects cardiac myocytes from hypoxia/reoxygenation-induced apoptosis via 
stimulation of Akt phosphorylation (Yao, Huang et al. 2010). Moreover, blockade of 
PI3K with LY294002 or Akt with Akt VIII significantly attenuated the inhibitory effect 
by NaHS on NHE-1 activity and its subsequent cardioprotection. To confirm the 
contribution of the PI3K/Akt pathway, we also observed the protective action of NaHS 
on heart contractile function in the presence or absence of Akt VIII, a specific inhibitor 
of Akt. Like LY294002, Akt VIII also attenuated the effect of H2S on cardiac 
contractile function. These data suggest that the cardioprotection of H2S involves the 
PI3K/Akt/NHE-1 pathway. Interestingly, recent studies showed that inhibition of 
NHE-1 may also stimulate Akt (Jung, Lee et al. 2010). These data suggest that 
activation of Akt and inhibition of NHE-1 may be co-dependent. In addition to Akt 
activation, Yao et al found H2S also inhibited GSK3β, and subsequently inhibited the 
opening of mitochondrial permeability transition pore (mPTP) (Yao, Huang et al. 2010). 
It is also demonstrated that NHE-1 inhibition may produce cardioprotection via 
phosphorylation and inhibition of GSK-3β (Jung, Lee et al. 2010). These findings 
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suggest that H2S may inhibit GSK-3β through inhibition of NHE-1 activity. 
    NHE-1 activity can also be regulated by PKG. A previous study showed that 
blockade of PKG restored the suppressed NHE-1 activity to normal (Perez, Piaggio et 
al. 2007). We therefore examined the involvement of PKG in the actions of NaHS. We 
found that blockade of PKG with KT5823 attenuated the effect of NaHS on NHE-1 
activity and its protective effects on post-ischemia-induced contractile function injury. 
This implies that PKG may also be involved in the regulation of NHE-1 activity by 
NaHS. This is verified by the PKG activity assay.  In fact, the NaHS treatment 
enhanced PKG activity in ischemic myocytes. Moreover, the increase of PKG activity 
could be blocked by the Akt inhibitor, indicating that Akt is upstream of PKG 
activation. The failure of the PKG inhibitor KT5823 to attenuate the NaHS-stimulated 
Akt activation again supports the evidence that activation of PKG is secondary to 
PI3K/Akt activation. 
    CBE is the major acid loader in the cardiovascular myocyte. Stimulation of this 
transporter would be expected to “dampen” the ability of the cell to maintain a normal 
pHi range and therefore decreases pHi. For this reason, we also observed the effect of 
H2S on CBE activity. We found that H2S inhibits, but not stimulates CBE. These data 
exclude the possibility that CBE contributes to the action of H2S in regulating pHi in the 
cardiac myocytes. 
    The mechanisms for NHE-1 inhibition-triggered cardioprotection have been well 
studied previously. Ischemia-induced protons leaving the myocytes via NHE-1 during 
reperfusion may lead to Na+ loading, which may subsequently induce Ca2+ over loading 
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as Na+ leaves the cell via the Na+/Ca2+ exchanger. The resultant rise in [Ca2+]i is 
believed to trigger Ca2+-activated proteases and phospholipases that cause the cellular 
damage  (Tani 1990; Pierce and Czubryt 1995). In addition, ischemia/reperfusion may 
also open mPTP. When the mPTP opens, the permeability barrier of the inner 
membrane becomes disrupted. This will result in mitochondrial swelling and break the 
outer membrane of mitochondria. The rupture of the outer membrane will lead to the 
release of proteins in the intermembrane space such as cytochrome c, AIF and other 
factors that play a critical role in apoptotic cell death. Once released, these factors 
activate caspase-9, which in turn activates caspase-3. This protease mediates the 
proteolytic cleavage of a range of proteins responsible for the rearrangement of the 
cytoskeleton, plasma membrane, and nucleus that are characteristic of apoptosis. A 
potent inhibitor of mPTP opening is low pH (Halestrap, Clarke et al. 2004). Therefore, 
in this way, NHE-1inhibition produces cardioprotection.  
    However, despite their great promise of cardioprotection in extensive preclinical 
work (Avkiran, Cook et al. 2008), clinical studies with NHE inhibitors were less 
convincing. It is shown that direct and global NHE inhibition may trigger non-cardiac 
adverse effects. Compared with NHE inhibitors, H2S may have better clinical 
application potential. This is because, apart from inhibition of NHE-1, H2S also 
protects the heart via suppression of β-adrenoceptor function, stimulation of various 
protein kinases and cardioprotective mediators such as PGE2 and nitric oxide (Bian, 
Yong et al. 2006; Hu, Pan et al. 2008; Pan, Neo et al. 2008; Yong, Pan et al. 2008; Pan, 
Chen et al. 2009). In addition, H2S has been found to be useful in treating heart failure 
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(Calvert, Elston et al. 2010), hypertrophy (Shi, Chen et al. 2007), and renin-dependent 
hypertension (Lu, Liu et al. 2010). These data suggest that H2S treatment may provide 
multiple cardioprotective effects. However, bearing in mind that the NHE inhibitors 
were not very successful in clinical development for cardioprotection despite the great 
promise shown in preclinical studies, the present preclinical study does not rule out the 
possibility of failed clinical application of H2S in ischemic heart disease. Clinical 
investigations are thus warranted to test the potential application of H2S. 
    In summary, my study shows that H2S decreases pHi in cardiac myocytes by 
inhibiting NHE-1 activity via a PI3K/Akt/PKG-dependent mechanism. This further 
offers cardioprotective effects against ischemia/reperfusion-induced injury. The unique 
action of H2S suggests a potential therapeutic application for H2S in ischemic condition 
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